Impact of Novel Approaches to Systemic Lupus Erythematosus: Evolution of Treatment and Management Strategies to Optimize Patients Care

Jointly provided by Med Learning Group and Amedco.

Supported by an Educational Grant from Lilly USA, LLC.

Scroll to the Bottom of this Information to Begin This Course

Release date: October 17, 2014

Valid through: October 17, 2015

Specialty: Rheumatology

Topic: Systemic Lupus Erythematosus

Estimated Time to Complete Activity: 60 minutes

Target Audience

This CME initiative is designed to meet the educational needs of pharmacists, specialty pharmacy professionals and other healthcare providers involved in the treatment of patients with systemic lupus.

Program Overview

This case-based enduring activity will discuss the treatment and management strategies to optimize care of patients with systemic lupus erythematosus.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Employ the new SLICC criteria to more accurately classify patients with mild, moderate, and severe disease, while reviewing potential limitation of disease activity indices and visual analog scales
  • Discuss the benefits and limitations of current agents for SLE and differentiate biologic therapies from conventional therapies
  • Evaluate clinical trial evidence for the potential safety, tolerability, and efficacy of agents in development for SLE
  • Discuss risk factors for comorbidities associated with SLE and their impact on treatment considerations
  • Outline the considerations for individualized treatment, strategies for setting treatment goals, and, predictive factors for nonadherence

Click the links below to review the activity launch pages containing full disclosure information.

Physicians — 1.5 AMA PRA Category 1 Credits

Pharmacists — 1.5 Contact Hours